Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Fawcett

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of the Royal Army Medical Corps|May 31, 2013
Operational medical force protection: the collective solutionC D Bonser, J R Fawcett
Brain Research|October 20, 1999
Previously reported nerve growth factor levels are underestimated due to an incomplete release from receptors and interaction with standard curve mediaJ R Fawcett, X Chen, Y E Rahman, et al.
Neuroscience Letters|July 18, 2001
Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusionX F Liu, J R Fawcett, R G Thorne, et al.
Journal of Molecular Neuroscience : MN|February 26, 2000
Anandamides inhibit binding to the muscarinic acetylcholine receptorS Lagalwar, E Z Bordayo, K L Hoffmann, et al.
Journal of the Neurological Sciences|July 7, 2001
Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damageX F Liu, J R Fawcett, R G Thorne, et al.
Journal of Molecular Neuroscience : MN|October 15, 1998
Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acidJ R Kjome, K A Swenson, M N Johnson, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of the Royal Army Medical Corps|May 31, 2013
Operational medical force protection: the collective solutionC D Bonser, J R Fawcett
Brain Research|October 20, 1999
Previously reported nerve growth factor levels are underestimated due to an incomplete release from receptors and interaction with standard curve mediaJ R Fawcett, X Chen, Y E Rahman, et al.
Neuroscience Letters|July 18, 2001
Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusionX F Liu, J R Fawcett, R G Thorne, et al.
Journal of Molecular Neuroscience : MN|February 26, 2000
Anandamides inhibit binding to the muscarinic acetylcholine receptorS Lagalwar, E Z Bordayo, K L Hoffmann, et al.
Journal of the Neurological Sciences|July 7, 2001
Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damageX F Liu, J R Fawcett, R G Thorne, et al.
Journal of Molecular Neuroscience : MN|October 15, 1998
Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acidJ R Kjome, K A Swenson, M N Johnson, et al.
Pageof 1